T2 Biosystems is disrupting the landscape of clinical diagnostics with T2MR, the Company's proprietary magnetic biosensor detector. The T2MR technology enables healthcare professionals to save lives and reduce costs by providing sensitive, accurate and rapid assay results. The Company's products detect molecular or immunoassay targets as well as hemostasis biomarkers directly from unpurified clinical samples in hospitals, labs and physicians' offices.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/28/13 | $40,000,000 | Series E |
Aisling Capital Arcus Ventures Flagship Ventures Flybridge Capital Partners Goldman Sachs Partners Healthcare Physic Ventures Polaris Partners WS Investments | undisclosed |
